Pharsight

1. Apretude patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103	VIIV HLTHCARE	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent	Apr, 2026 (2 years from now)
US10927129	VIIV HLTHCARE	N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity	Apr, 2026 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597	VIIV HLTHCARE	Pharmaceutical compositions	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
600MG/3ML (200MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

APRETUDE family patents

2. Cabenuva Kit patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP07786802A	2018-10-23	HGF Limited	Opposition rejected
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP04787096A	2016-01-22	Page White & Farrer Limited	Patent maintained as amended
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed
EP05108086A	2012-02-09	Hamm, Volker	The patent has been limited

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11389447	October, 2020	Decision	JANSSEN SCIENCES IRELAND UC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6838464	VIIV HLTHCARE	2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents	Feb, 2021 (3 years ago)
US8080551	VIIV HLTHCARE	HIV inhibiting pyrimidines derivatives	Apr, 2023 (1 year, 17 days ago)
US7125879	VIIV HLTHCARE	HIV inhibiting pyrimidines derivatives	Apr, 2025 (11 months from now)
US10927129	VIIV HLTHCARE	N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity	Apr, 2026 (2 years from now)
US8410103	VIIV HLTHCARE	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent	Apr, 2026 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447	VIIV HLTHCARE	Aqueous suspensions of TMC278	Jun, 2027 (3 years from now)
US11224597	VIIV HLTHCARE	Pharmaceutical compositions	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 21, 2026
New Patient Population(NPP)	Mar 29, 2025
New Dosing Schedule(D-184)	Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

CABENUVA KIT family patents

3. Combivir patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082	VIIV HLTHCARE	Crystalline oxathiolane derivatives	May, 2016 (7 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5859021 (Pediatric)	VIIV HLTHCARE	Antiviral combinations	Nov, 2012 (11 years ago)
US5905082 (Pediatric)	VIIV HLTHCARE	Crystalline oxathiolane derivatives	Nov, 2016 (7 years ago)

Drugs and Companies using LAMIVUDINE; ZIDOVUDINE ingredient

Market Authorisation Date: 26 September, 1997

Treatment: Treatment of hiv

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;300MG	TABLET;ORAL	Prescription

COMBIVIR family patents

4. Dovato patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16187411A	2019-05-22	Sandoz AG	Granted and Under Opposition
EP16187411A	2019-05-22	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP16187411A	2019-05-22	STADA Arzneimittel AG	Granted and Under Opposition
EP16187411A	2019-05-20	Cooke, Richard	Granted and Under Opposition
EP15164931A	2018-12-21	Cooke, Richard	Granted and Under Opposition
EP15164931A	2018-12-19	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP11737484A	2016-02-05	LEK Pharmaceuticals d.d.	Revoked
EP11737484A	2016-02-05	Page White & Farrer Limited	Revoked
EP11737484A	2016-02-04	Ter Meer Steinmeister & Partner Patentanwälte mbB	Revoked
EP11737484A	2016-02-03	Teva Pharmaceutical Industries Ltd	Revoked
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (3 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385 (Pediatric)	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Apr, 2028 (3 years from now)
US9242986 (Pediatric)	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Jun, 2030 (6 years from now)
US11234985	VIIV HLTHCARE	Antiviral therapy	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Apr 08, 2022
New Indication(I-839)	Aug 06, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/300 mg	30 Jul, 2019	1		08 Dec, 2029

Strength	Dosage	Availability
EQ 50MG BASE;300MG	TABLET;ORAL	Prescription

DOVATO family patents

5. Epivir patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082	VIIV HLTHCARE	Crystalline oxathiolane derivatives	May, 2016 (7 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5905082 (Pediatric)	VIIV HLTHCARE	Crystalline oxathiolane derivatives	Nov, 2016 (7 years ago)
US6004968	VIIV HLTHCARE	Pharmaceutical compositions containing lamivudine	Mar, 2018 (6 years ago)
US6004968 (Pediatric)	VIIV HLTHCARE	Pharmaceutical compositions containing lamivudine	Sep, 2018 (5 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-147)	Mar 23, 2018

Drugs and Companies using LAMIVUDINE ingredient

Market Authorisation Date: 17 November, 1995

Treatment: Treatment of hiv

Dosage: SOLUTION;ORAL; TABLET;ORAL

Strength	Dosage	Availability
10MG/ML	SOLUTION;ORAL	Prescription
300MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription

EPIVIR family patents

6. Epzicom patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082	VIIV HLTHCARE	Crystalline oxathiolane derivatives	May, 2016 (7 years ago)
US6294540	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	May, 2018 (5 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6417191	VIIV HLTHCARE	Synergistic combinations of zidovudine, 1592U89 and 3TC	Mar, 2016 (8 years ago)
US6417191 (Pediatric)	VIIV HLTHCARE	Synergistic combinations of zidovudine, 1592U89 and 3TC	Sep, 2016 (7 years ago)
US5905082 (Pediatric)	VIIV HLTHCARE	Crystalline oxathiolane derivatives	Nov, 2016 (7 years ago)
US6294540 (Pediatric)	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	Nov, 2018 (5 years ago)

Drugs and Companies using ABACAVIR SULFATE; LAMIVUDINE ingredient

Market Authorisation Date: 02 August, 2004

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
600 mg/300 mg	27 Sep, 2007	1	29 Sep, 2016	14 May, 2018	Eligible

Strength	Dosage	Availability
EQ 600MG BASE;300MG	TABLET;ORAL	Prescription

EPZICOM family patents

7. Juluca patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16187411A	2019-05-22	Sandoz AG	Granted and Under Opposition
EP16187411A	2019-05-22	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP16187411A	2019-05-22	STADA Arzneimittel AG	Granted and Under Opposition
EP16187411A	2019-05-20	Cooke, Richard	Granted and Under Opposition
EP15164931A	2018-12-21	Cooke, Richard	Granted and Under Opposition
EP15164931A	2018-12-19	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP11737484A	2016-02-05	LEK Pharmaceuticals d.d.	Revoked
EP11737484A	2016-02-05	Page White & Farrer Limited	Revoked
EP11737484A	2016-02-04	Ter Meer Steinmeister & Partner Patentanwälte mbB	Revoked
EP11737484A	2016-02-03	Teva Pharmaceutical Industries Ltd	Revoked
EP04787096A	2016-01-22	Page White & Farrer Limited	Patent maintained as amended
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed
EP05108086A	2012-02-09	Hamm, Volker	The patent has been limited

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7067522	VIIV HLTHCARE	2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents	Dec, 2019 (4 years ago)
US6838464	VIIV HLTHCARE	2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents	Feb, 2021 (3 years ago)
US8080551	VIIV HLTHCARE	HIV inhibiting pyrimidines derivatives	Apr, 2023 (1 year, 17 days ago)
US7125879	VIIV HLTHCARE	HIV inhibiting pyrimidines derivatives	Apr, 2025 (11 months from now)
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (3 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)
US10426780	VIIV HLTHCARE	Antiviral therapy	Jan, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629	VIIV HLTHCARE	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile	Aug, 2022 (1 year, 8 months ago)
US8129385 (Pediatric)	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Apr, 2028 (3 years from now)
US9242986 (Pediatric)	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Jun, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 12, 2018
New Combination(NC)	Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/25 mg	19 Nov, 2019	1		24 Jan, 2031

Strength	Dosage	Availability
EQ 50MG BASE;EQ 25MG BASE	TABLET;ORAL	Prescription

JULUCA family patents

8. Lexiva patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6436989	VIIV HLTHCARE	Prodrugs of aspartyl protease inhibitors	Dec, 2017 (6 years ago)
US6514953	VIIV HLTHCARE	Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate	Jul, 2019 (4 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6436989 (Pediatric)	VIIV HLTHCARE	Prodrugs of aspartyl protease inhibitors	Jun, 2018 (5 years ago)
US6514953 (Pediatric)	VIIV HLTHCARE	Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate	Jan, 2020 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Oct 27, 2015
New Patient Population(NPP)	Apr 27, 2015

Drugs and Companies using FOSAMPRENAVIR CALCIUM ingredient

Market Authorisation Date: 20 October, 2003

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL; SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
700 mg	18 Jan, 2012	1	20 Nov, 2019	15 Jul, 2019	Extinguished

Strength	Dosage	Availability
EQ 700MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE/ML	SUSPENSION;ORAL	Discontinued

LEXIVA family patents

9. Rescriptor patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5563142	VIIV HLTHCARE	Diaromatic substituted compounds as anti-HIV-1 agents	Oct, 2013 (10 years ago)
US6177101	VIIV HLTHCARE	Delavirdine high strength tablet formulation	Jun, 2019 (4 years ago)

Drugs and Companies using DELAVIRDINE MESYLATE ingredient

Market Authorisation Date: 04 April, 1997

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Discontinued
200MG	TABLET;ORAL	Discontinued

RESCRIPTOR family patents

10. Rukobia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461333	VIIV HLTHCARE	Salts of prodrugs of piperazine and substituted piperidine antiviral agents	Feb, 2025 (9 months from now)
US7745625	VIIV HLTHCARE	Prodrugs of piperazine and substituted piperidine antiviral agents	Nov, 2027 (3 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168615	VIIV HLTHCARE	Prodrugs of piperazine and substituted piperidine antiviral agents	Feb, 2025 (9 months from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 02, 2025

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

NCE-1 date: 02 July, 2024

Market Authorisation Date: 02 July, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 600MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

RUKOBIA family patents

11. Selzentry patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6586430	VIIV HLTHCARE	CCR5 modulators	Dec, 2019 (4 years ago)
US7576097	VIIV HLTHCARE	Tropane derivatives useful in therapy	May, 2021 (2 years ago)
US6667314	VIIV HLTHCARE	Tropane derivatives useful in therapy	Aug, 2021 (2 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7576097 (Pediatric)	VIIV HLTHCARE	Tropane derivatives useful in therapy	Nov, 2021 (2 years ago)
US6667314 (Pediatric)	VIIV HLTHCARE	Tropane derivatives useful in therapy	Feb, 2022 (2 years ago)
US7368460	VIIV HLTHCARE	Tropane derivatives useful in therapy	Nov, 2022 (1 year, 5 months ago)
US7368460 (Pediatric)	VIIV HLTHCARE	Tropane derivatives useful in therapy	May, 2023 (11 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	May 28, 2013
New Strength(NS)	Nov 04, 2019
New Chemical Entity Exclusivity(NCE)	Aug 06, 2012

Drugs and Companies using MARAVIROC ingredient

NCE-1 date: 07 August, 2011

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL; SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg and 300 mg	08 Aug, 2011	2	07 Feb, 2022	25 Nov, 2022	Eligible

Strength	Dosage	Availability
300MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
25MG	TABLET;ORAL	Prescription
20MG/ML	SOLUTION;ORAL	Prescription
75MG	TABLET;ORAL	Prescription

SELZENTRY family patents

12. Tivicay patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (3 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385 (Pediatric)	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Apr, 2028 (3 years from now)
US9242986 (Pediatric)	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Jun, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-758)	Nov 21, 2020
New Chemical Entity Exclusivity(NCE)	Aug 12, 2018
M(M-166)	Jul 30, 2018

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 09 June, 2016

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg, 25 mg and 50 mg	14 Aug, 2017	4		08 Dec, 2029

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE	TABLET;ORAL	Prescription

TIVICAY family patents

13. Tivicay Pd patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (3 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385 (Pediatric)	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Apr, 2028 (3 years from now)
US9242986 (Pediatric)	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Jun, 2030 (6 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Market Authorisation Date: 12 June, 2020

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg	21 Jul, 2021	1		08 Dec, 2029

Strength	Dosage	Availability
EQ 5MG BASE	TABLET, FOR SUSPENSION;ORAL	Prescription

TIVICAY PD family patents

14. Triumeq patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082	VIIV HLTHCARE	Crystalline oxathiolane derivatives	May, 2016 (7 years ago)
US6294540	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	May, 2018 (5 years ago)
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (3 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6417191	VIIV HLTHCARE	Synergistic combinations of zidovudine, 1592U89 and 3TC	Mar, 2016 (8 years ago)
US6417191 (Pediatric)	VIIV HLTHCARE	Synergistic combinations of zidovudine, 1592U89 and 3TC	Sep, 2016 (7 years ago)
US5905082 (Pediatric)	VIIV HLTHCARE	Crystalline oxathiolane derivatives	Nov, 2016 (7 years ago)
US6294540 (Pediatric)	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	Nov, 2018 (5 years ago)
US8129385 (Pediatric)	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Apr, 2028 (3 years from now)
US9242986 (Pediatric)	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Jun, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-294)	Jun 15, 2026
Pediatric Exclusivity(PED)	Dec 15, 2026
New Chemical Entity Exclusivity(NCE)	Aug 12, 2018
New Dosing Schedule(D-147)	Mar 23, 2018

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

NCE-1 date: 15 December, 2025

Market Authorisation Date: 22 August, 2014

Treatment: Treatment of human immunodeficiency virus (hiv) infection.

Dosage: TABLET;ORAL

TRIUMEQ family patents

15. Triumeq Pd patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (3 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385 (Pediatric)	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Apr, 2028 (3 years from now)
US9242986 (Pediatric)	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Jun, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 15, 2026
Pediatric Exclusivity(PED)	Dec 15, 2026

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 30 March, 2022

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

TRIUMEQ PD family patents

16. Trizivir patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082	VIIV HLTHCARE	Crystalline oxathiolane derivatives	May, 2016 (7 years ago)
US6294540	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	May, 2018 (5 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6417191	VIIV HLTHCARE	Synergistic combinations of zidovudine, 1592U89 and 3TC	Mar, 2016 (8 years ago)
US6417191 (Pediatric)	VIIV HLTHCARE	Synergistic combinations of zidovudine, 1592U89 and 3TC	Sep, 2016 (7 years ago)
US5905082 (Pediatric)	VIIV HLTHCARE	Crystalline oxathiolane derivatives	Nov, 2016 (7 years ago)
US6294540 (Pediatric)	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	Nov, 2018 (5 years ago)

Drugs and Companies using ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE ingredient

Market Authorisation Date: 14 November, 2000

Treatment: Treatment of hiv; Method of treatment of a patient infected with hiv

Dosage: TABLET;ORAL

TRIZIVIR family patents

17. Vocabria patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103	VIIV HLTHCARE	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent	Apr, 2026 (2 years from now)
US10927129	VIIV HLTHCARE	N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity	Apr, 2026 (2 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 21, 2026
New Patient Population(NPP)	Mar 29, 2025
M(M-273)	Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR SODIUM ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: TABLET;ORAL

VOCABRIA family patents

18. Ziagen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6294540	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	May, 2018 (5 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6294540 (Pediatric)	VIIV HLTHCARE	Carbocyclic nucleoside hemisulfate and its use in treating viral infections	Nov, 2018 (5 years ago)
US6641843	VIIV HLTHCARE	Pharmaceutical compositions	Feb, 2019 (5 years ago)
US6641843 (Pediatric)	VIIV HLTHCARE	Pharmaceutical compositions	Aug, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-147)	Mar 23, 2018

Drugs and Companies using ABACAVIR SULFATE ingredient

Market Authorisation Date: 17 December, 1998

Treatment: Method of treatment of a patient infected with hiv

Dosage: SOLUTION;ORAL; TABLET;ORAL

Pharsight

Viiv Hlthcare patents expiration

1. Apretude patents expiration

APRETUDE family patents

2. Cabenuva Kit patents expiration

CABENUVA KIT family patents

3. Combivir patents expiration

COMBIVIR family patents

4. Dovato patents expiration

DOVATO family patents

5. Epivir patents expiration

EPIVIR family patents

6. Epzicom patents expiration

EPZICOM family patents

7. Juluca patents expiration

JULUCA family patents

8. Lexiva patents expiration

LEXIVA family patents

9. Rescriptor patents expiration

RESCRIPTOR family patents

10. Rukobia patents expiration

RUKOBIA family patents

11. Selzentry patents expiration

SELZENTRY family patents

12. Tivicay patents expiration

TIVICAY family patents

13. Tivicay Pd patents expiration

TIVICAY PD family patents

14. Triumeq patents expiration

TRIUMEQ family patents

15. Triumeq Pd patents expiration

TRIUMEQ PD family patents

16. Trizivir patents expiration

TRIZIVIR family patents

17. Vocabria patents expiration

VOCABRIA family patents

18. Ziagen patents expiration

ZIAGEN family patents

Related content

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg	28 Jan, 2009	1	18 Jun, 2012	14 May, 2018	Eligible
20 mg/mL	27 Dec, 2012	1	26 Sep, 2016	14 May, 2018	Eligible

Strength	Dosage	Availability
EQ 20MG BASE/ML	SOLUTION;ORAL	Prescription
EQ 300MG BASE	TABLET;ORAL	Discontinued